Clinical Microbiology and Antimicrobial Chemotherapy. 2022; 24(2):93-107
Objective. To evaluate safety of anti-interleukin drugs used as a pathogenetic therapy of COVID-19 as assessed by risks of infectious complications.
Materials and Methods. A systematic review of publications related to safety assessment of anti-interleukin drugs recommended as pathogenetic therapy in COVID-19 patients in terms of incidence of serious adverse events and adverse events of “Infections and Invasions” class and a meta-analysis of the data were performed.
Results. The meta-analysis included 16 randomized and 3 non-randomized studies.